A model for neutralization of viruses based on antibody coating of the virion surface

Current Topics in Microbiology and Immunology

Volumn 260, Issue , 2001, Pages 109-143

  Burton, D R ^a   Saphire, E O ^a   Parren, P W H I ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; CONFORMATIONAL TRANSITION; HOST CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNITY; MOLECULAR MODEL; NONHUMAN; PICORNAVIRUS; PRIORITY JOURNAL; PROTEIN CONFORMATION; RABIES VIRUS; REVIEW; VIRION; VIRUS INFECTION; VIRUS NEUTRALIZATION;

ADENOVIRIDAE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; PICORNAVIRIDAE; RABIES VIRUS;

EID: 0034972940     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-662-05783-4_7     Document Type: Review

References (137)

1. Identification of the residues in human CD4 critical for the binding of HIV
2. Cellular proteins bound to immunodeficiency viruses: Implications for pathogenesis and vaccines
3. Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus
4. Kinetics of neutralization of sensitized herpes simplex virus with antibody fragments
5. Kinetics of sensitization of herpes simplex virus and its relationship to the reduction in the neutralization rate constant
6. Internalization of the human immunodeficiency virus does not require the cytoplasmic domain of CD4
7. Over een Contagium vivum fluidum als oorzaak van de vlekziekte der tabaksbladen
8. Three-dimensional structure of poliovirus receptor bound to poliovirus
9. HIV entry and tropism: The chemokine receptor connection
10. Structural studies on viral escape from antibody neutralization
11. Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site
12. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dlgA or IgM
13. Two antibodies that neutralize papillomavirus by different mechanisms show distinct binding patterns at 13Å resolution
14. Complement receptor type 2 mediates infection of the human CD4-negative Raji B-cell line with opsonized HIV
15. Lack of quantitative correlation between the neutralization of poliovirus and the antibody-mediated pl shift of the virions
16. The immunological reactions of the filterable viruses
17. Vaccines and the induction of functional antibodies: Time to look beyond the molecules of natural infection?
18. Antibody and virus: Binding and neutralization
19. A simple and reliable method to detect cell membrane proteins on infectious human immunodeficiency virus type 1 particles
20. Antibody-mediated neutralization of human rhinovirus 14 explored by means of cryoelectron microscopy and X-ray crystallography of virus-Fab complexes
21. Inhibition of rhinovirus attachment by neutralizing monoclonal antibodies and their Fab fragments
22. Fc receptors for IgG (FcγRs) on human monocytes and macrophages are not infectivity receptors for human immunodeficiency virus type 1 (HIV-1): Studies using bispecific antibodies to target HIV-1 to various myeloid cell surface molecules, including the FcγR
23. Natural variation of poliovirus neutralization epitopes
24. A multi-hit model for the neutralization of animal viruses
25. Antigenic variation and resistance to neutralization in poliovirus type 1
26. Neutralization of animal viruses
27. Analysis of the cleavage site of the human immunodeficiency virus type 1 glycoprotein: Requirement of precursor cleavage for glycoprotein incorporation
28. A study of the basic aspects of neutralization of two animal viruses, western equine encephalitis virus and poliomyelitis virus
29. Functional basis of poliovirus neutralization determined with monospecific neutralizing antibodies
30. Bivalent attachment of antibody onto poliovirus leads to conformational alteration and neutralization
31. Mechanisms of rabies virus neutralization
32. A complex of influenza hemagglutinin with a neutralizing antibody that binds outside the virus receptor binding site
33. Antibody-mediated activation of Sindbis virus
34. Immunocytochemical colocalization of specific immunoglobulin A with sendai virus protein in infected polarized epithelium
35. MHC-antigens: Constituents of the envelopes of human and simian immunodeficiency viruses
36. Assembly and morphology of HIV: Potential effect of structure on viral function
37. Immune enhancement of viral infection
38. The enhancement of virus infectivity by antibody
39. Interaction of the poliovirus receptor with poliovirus
40. - cells from virus binding
41. Structural studies on antibody interacting with viruses
42. Structure of a neutralizing antibody bound bivalently to human rhinovirus 2
43. The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells
44. Nonrandom association of cellular antigens with HTLV-III virions
45. Neutralization of poliovirus by a monoclonal antibody: Kinetics and stoichiometry
46. Extracellular enveloped vaccinia virus escapes neutralization
47. Monoclonal antibodies to Newcastle disease virus: Delineation of four epitopes on the HN glycoprotein
48. Neutralization of Newcastle disease virus by monoclonal antibodies to the hemagglutinin-neuraminidase glycoprotein: Requirement for antibodies to four sites for complete neutralization
49. The development of the phage-inactivating properties of serum during the course of specific immunization of an animal: Reversible and irreversible inactivation
50. Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency viruses
51. Role of mucosal antibodies in viral infections
52. Antiviral activity of antiserum specific for an influeza virus neuraminidase
53. Phenotypic mixing of vesicular stomatitis virus with HVJ (Sendai virus)
54. Enhanced neutralization of La Crosse virus by the binding of specific pairs of monoclonal antibodies to the G1 glycoprotein
55. Quantitative model of antibody-and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1
56. A mathematical and experimental study of the kinetics of neutralization of bacteriophage φX 174 by antibodies
57. The interaction between virus and antibody
58. The interaction between virus and antibody II. Mechanism of the reaction
59. Orthomyxoviridia: The viruses and their replication
60. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function
61. Neutralization of feline leukemia virus with feline antisera to leukocyte alloantigens
62. Incomplete neutralization of hepatitis A virus in vitro due to lipid-associated virions
63. Human cytomegalovirus neutralizing antibody-resistant phenotype is associated with reduced expression of glycoprotein H
64. Increased adhesion as a mechanism of antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus infection
65. Reversibility of the reaction between poliovirus and neutralizing antibody of rabbit origin
66. Neutralization of poliovirus: A hypothesis to explain the mechanism and the one-hit character of the neutralization reaction
67. Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies
68. Comparison of IgA versus IgG monoclonal antibodies for passive immunization of the murine respiratory tract
69. Summary report: Workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials
70. Viral epitopes and monoclonal antibodies: Isolation of blocking antibodies that inhibit virus neutralization
71. Opsonization-enhanced phagocytosis of foot-and-mouth disease virus
72. Single- and multi-hit kinetics of immunoglobulin G neutralization of human immunodeficiency virus type 1 by monoclonal antibodies
73. Functional epitope analysis of the human CD4 molecule. The MHC class II-dependent activation of resting T cells is inhibited by monoclonal antibodies to CD4 regardless whether or not they recognize epitopes involved in the binding of MHC class II or HIV gp120
74. Immunological studies of the functions of paramyxovirus glycoproteins
75. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120
76. HIV-1 neutralization: The consequences of viral adaptation to growth on transformed T cells
77. Profiles of antibody-dependent enhancement of dengue virus type 2 infection
78. Association of serum anti-neuraminidase antibody with resistance to influenza in man
79. Orthomyxoviruses
80. Virus neutralization and virus-induced immune complex disease. Virus-antibody union resulting in immunoprotection or immunology injury-two sides of the same coin
81. Association of host cell surface adhesion receptors and other membrane proteins with HIV and SIV
82. Antibodies against HIV-1 from phage display libraries: Mapping of an immune response and progress towards antiviral immunotherapy
83. The anti-viral activity of antibodies in vitro and in vivo
84. HIV-1 antibody - Debris or virion?
85. Neutralization of HIV-1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity
86. The neutralizing antibody response to HIV-1: Viral evasion and escape from humoral immunity
87. Neutralization of Chlamydia trachomatis: Kinetics and stoichiometry
88. Interaction between poliovirus and immunoglobulins. II. Basic aspects of virus-antibody interaction
89. Interaction between poliovirus and immunoglobulins. I. Detection of virus antibodies by partition in aqueous polymer phase systems
90. Studies on the mechanism of neutralization of influenza virus by antibody: Evidence that neutralizing antibody (anti-haemagglutinin) inactivates influenza virus in vivo by inhibiting virion transcriptase activity
91. Challenges for development of hepatitis C virus vaccines
92. Two parallel routes of the complement-mediated antibody-dependent enhancement of HIV-1 infection
93. An analysis of the inactivation of MS2 bacteriophage with antiserum
94. Monoclonal antibodies which recognize the acidic configuration of the rabies glycoprotein at the surface of the virion can be neutralizing
95. Contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization
96. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1
97. Antibody-dependent enhancement of human immunodeficiency virus type 1 infection
98. Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins
99. Picornaviridae: The viruses and their replication
100. Detection of HLA-DR associated with monocytotropic, primary, and plasma isolates of human immunodeficiency virus type 1
101. Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: Significance for subunit vaccines
102. Reduced surface: An efficient way to compute molecular surfaces
103. Epitopes of the CD4 antigen and HIV infection
104. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer
105. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules
106. Stoichiometry of monoclonal anitbody neutralization of T-cell line-adapted human immunodefiency virus type 1
107. Enhancement of infectivity of a non-syncytium inducing HIV-1 by sCD4 and by human antibodies that neutralize syncytium inducing HIV-1
108. Rapidity of specific antibody-antigen interactions
109. Antibody interactions with rhinovirus; lessons for mechanisms of neutralization and the role of immunity in viral evolution
110. Neutralising antibody to human rhinovirus 14 penetrates the receptor-binding canyon
111. Structure of human rhinovirus complexed with Fab fragments from a neutralizing antibody
112. Cryo-EM visualization of an exposed RGD epitope on adenovirus that escapes antibody neutralization
113. Recent structural solutions for antibody neutralization of viruses
114. Towards a vaccine against AIDS: Lessons from simian immunodeficiency virus vaccines
115. Complement can neutralize HIV-1 plasma virus by a C5-independent mechanism
116. Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies
117. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates
118. Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry
119. Quantitative relationships between an influenza virus and neutralizing antibody
120. A region in domain 1 of CD4 distinct from the primary gp120 binding site is involved in HIV infection and virus-mediated fusion
121. + target cells is a major mechanism of T cell line-adapted HIV-1 neutralization
122. Beijerinck's contribution to the virus concept-an introduction
123. Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation
124. Electron microscopic studies on the structure of rabies virus
125. Effect of the cytoplasmic domain of the simian immunodeficiency virus envelope protein on incorporation of heterologous envelope proteins and sensitivity to neutralization
126. Rhabdoviridae: The viruses and their replication
127. Virus aggregation as the cause of the non-neutralizable persistent fraction
128. Herpesvirus neutralization: Induction of the persistent fraction by insufficient antibody
129. Preparation and properties of antibody directed specifically against the neuraminidase of influenza virus
130. Monoclonal antibodies to GP5 of porcine reproductive and respiratory syndrome virus are more effective in virus neutralization than monoclonal antibodies to GP4
131. The neutralization of arboviruses. I. Neutralization in homologous virus-serum mixtures with two group B arboviruses
132. Vesicular stomatitis virus (measles) pseudotypes: Tool for demonstrating defective measles infections
133. Ultrastructural analysis of developmental events in Chlamydia pneumoniae-infected cells
134. Dimeric association and segmental variability in the structure of human CD4
135. Phenotypic mixing of vesicular stomatitis virus with fowl plague virus
136. Influenza A virus M2 protein: Monoclonal antibody restriction of virus growth and detection of M2 in virions